The Development of Galectin-1 for Head and Neck Cancer

Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.

According to Nambiar, Galectin-1 is a target that should continue to be developed in combinatorial approaches so that it can eventually be investigated in clinical trials.

Additionally, it might be important to study Galectin-1 in different cancer types to determine if there is a similar correlation to what is demonstrated in head and neck cancer, states Nambiar.